Neonatal Pertussis, an Under-Recognized Health Burden and Rationale for Maternal Immunization: A Systematic Review of South and South-East Asian Countries.

Asia Epidemiology Maternal Immunization Neonatal Newborns Pertussis

Journal

Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 05 02 2019
pubmed: 6 5 2019
medline: 6 5 2019
entrez: 5 5 2019
Statut: ppublish

Résumé

Pertussis is an under-recognized cause of neonatal morbidity and mortality. To review information on the epidemiology and disease burden of neonatal pertussis in South and Southeast Asian countries, a systematic literature review of three bibliographic databases was undertaken. Peer-reviewed original studies on neonatal pertussis epidemiology and burden published since 2000, with a geographical scope limited to South and Southeast Asian countries, were included. Data were systematically extracted based on parameters defined a priori. Our findings show that the burden of neonatal pertussis and its complications is substantial. An increase in the number of pertussis cases has been noted since early 2000, ranging from 61 to 92.9% in infants 0-3 months old. The most common symptoms an infant is likely to present with are cough with or without paroxysms, cyanosis, apnea, tachypnea, difficulty in breathing and leukocytosis. In addition, it can lead to hospitalization (length of stay: 5-7 days), complications (e.g., pneumonia, seizures) and mortality ranging from 5.6 to 14.7%. Other observations indicate that diagnosis is challenging because of non-specific clinical symptoms. Specifically, for obstetricians and gynecologists, the information available for making informed decisions on the prevention of neonatal pertussis is unreliable. Maternal immunization against pertussis during late stages of pregnancy has proven to be efficacious and well tolerated. A high burden of neonatal pertussis, as well as its complications, is observed in South and Southeast Asian countries. There is a need to intensify efforts to protect this vulnerable population with maternal vaccination.Funding: GlaxoSmithKline Biologicals SAPlain Language Summary: Plain language summary available for this article. Please see Fig. 1 and the following link: https://doi.org/10.6084/m9.figshare.7951187 .

Identifiants

pubmed: 31054089
doi: 10.1007/s40121-019-0245-2
pii: 10.1007/s40121-019-0245-2
pmc: PMC6522626
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

139-153

Subventions

Organisme : GlaxoSmithKline Biologicals SA
ID : NA

Références

Pediatr Infect Dis J. 2005 May;24(5 Suppl):S25-34
pubmed: 15876920
Pediatr Infect Dis J. 2005 May;24(5 Suppl):S58-61
pubmed: 15876927
Indian Pediatr. 2008 Sep;45(9):723-7
pubmed: 18820374
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Indian Pediatr. 2009 Nov;46(11):1017-20
pubmed: 19671950
Vaccine. 2011 Mar 16;29(13):2503-7
pubmed: 21211584
MMWR Morb Mortal Wkly Rep. 2011 Oct 21;60(41):1424-6
pubmed: 22012116
Crit Rev Microbiol. 2012 May;38(2):111-21
pubmed: 22103249
Clin Infect Dis. 2012 Jun;54(12):1756-64
pubmed: 22431797
Hum Vaccin Immunother. 2012 Oct;8(10):1439-42
pubmed: 22894950
Southeast Asian J Trop Med Public Health. 2012 May;43(3):699-711
pubmed: 23077850
J Emerg Med. 2013 Apr;44(4):889-95
pubmed: 23287746
Vaccine. 2013 Dec 9;31(51):6087-91
pubmed: 24099874
Eur J Clin Microbiol Infect Dis. 2014 May;33(5):805-8
pubmed: 24292098
Indian Pediatr. 2013 Nov 8;50(11):1001-9
pubmed: 24382899
Expert Rev Vaccines. 2014 Oct;13(10):1167-74
pubmed: 25142439
Epidemiol Health. 2014 Nov 11;36:e2014030
pubmed: 25420951
Hum Vaccin Immunother. 2014;10(7):2118-22
pubmed: 25424828
Paediatr Respir Rev. 2015 Mar;16(2):112-8
pubmed: 25613084
Enferm Infecc Microbiol Clin. 2015 Mar;33(3):190-6
pubmed: 25707329
Pediatrics. 2015 Jun;135(6):990-9
pubmed: 25941302
BMJ. 2015 Jun 01;350:h2975
pubmed: 26032894
Yonsei Med J. 2015 Jul;56(4):1071-8
pubmed: 26069132
Clin Infect Dis. 2015 Oct 1;61(7):1099-106
pubmed: 26082502
Clin Infect Dis. 2015 Dec 1;61(11):1645-7
pubmed: 26374815
Clin Infect Dis. 2015 Dec 1;61(11):1637-44
pubmed: 26374816
Pediatr Infect Dis J. 2015 Sep;34(9):e222-32
pubmed: 26376316
Vaccine. 2016 Mar 14;34(12):1423-5
pubmed: 26562318
J Pediatric Infect Dis Soc. 2013 Mar;2(1):1-6
pubmed: 26619437
Proc Biol Sci. 2016 Jan 13;283(1822):null
pubmed: 26763701
Vaccine. 2016 Jun 30;34(31):3613-9
pubmed: 27142328
Clin Infect Dis. 2017 Jan 1;64(1):9-14
pubmed: 27624956
Clin Infect Dis. 2016 Dec 1;63(suppl 4):S119-S122
pubmed: 27838663
Clin Infect Dis. 2016 Dec 1;63(suppl 4):S123-S133
pubmed: 27838664
Clin Infect Dis. 2016 Dec 1;63(suppl 4):S148-S153
pubmed: 27838667
J Pediatric Infect Dis Soc. 2017 Mar 1;6(1):33-39
pubmed: 28073985
Vaccine. 2017 Feb 15;35(7):993-996
pubmed: 28109708
Arch Dis Child Fetal Neonatal Ed. 2017 Sep;102(5):F456-F463
pubmed: 28468899
Lancet Infect Dis. 2017 Sep;17(9):889-890
pubmed: 28623145
Pediatr Infect Dis J. 2018 Mar;37(3):202-205
pubmed: 28737623
Obstet Gynecol. 2017 Sep;130(3):e153-e157
pubmed: 28832489
Vaccine. 2017 Nov 7;35(47):6422-6428
pubmed: 29032896
Vaccine. 2017 Dec 4;35(48 Pt B):6766-6773
pubmed: 29037576
MMWR Morb Mortal Wkly Rep. 2017 Oct 20;66(41):1105-1108
pubmed: 29049273
Ann Med. 2018 May;50(3):193-208
pubmed: 29308916
Vaccine. 2018 Mar 27;36(14):1887-1892
pubmed: 29501321
PLoS One. 2018 Jun 14;13(6):e0197867
pubmed: 29902184

Auteurs

Ashish Agrawal (A)

Medical Affairs Department, GSK, Mumbai, India. ashish.8.agrawal@gsk.com.

Sanjeev Singh (S)

Medical Affairs Department, GSK, Mumbai, India.

Shafi Kolhapure (S)

Medical Affairs Department, GSK, Mumbai, India.

Walid Kandeil (W)

R&D Department, GSK, Wavre, Belgium.

Rishma Pai (R)

Lilavati, Jaslok, and Hinduja Hospitals, Mumbai, India.

Tanu Singhal (T)

Kokilaben Dhirubhai Ambani Hospital, Mumbai, India.

Classifications MeSH